Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,058 result(s) found for: Prior Placebo. Displaying page 287 of 353.
    «« First « Previous 283  284  285  286  287  288  289  290  291  Next» Last»»
    EudraCT Number: 2015-003812-19 Sponsor Protocol Number: ZPL389/102 Start Date*: 2015-12-07
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT ...
    Medical condition: PLAQUE PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-000053-23 Sponsor Protocol Number: SP0977 Start Date*: 2011-08-17
    Sponsor Name:UCB Biosciences GmbH
    Full Title: Multicenter, double-blind, placebo-controlled, two-arm, randomized, parallel, treatment intervention, sleep lab phase 4 study to assess the effect of rotigotine on nocturnal blood pressure in patie...
    Medical condition: Restless Legs Syndrome (RLS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004643-20 Sponsor Protocol Number: ID-078A302 Start Date*: 2018-06-18
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder
    Medical condition: Insomnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10022437 Insomnia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) FI (Completed) DE (Completed) SE (Completed) FR (Completed) CZ (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-002907-15 Sponsor Protocol Number: AC-051-350 Start Date*: 2007-03-21
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, ...
    Medical condition: Cardiac Surgery, Separation from cardiopulmonary bypass
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063082 Acute right ventricular failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) SK (Completed) IT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002270-31 Sponsor Protocol Number: 1275.9 Start Date*: 2012-12-19
    Sponsor Name:Boehringer Ingelheim España, S.A
    Full Title: A phase III, randomised, double-blind, parallel group, 24 week study to evaluate efficacy and safety of once daily empagliflozin 10 mg and 25 mg compared to placebo, all administered as oral fixed ...
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NO (Completed) IT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005288-86 Sponsor Protocol Number: C87077 Start Date*: 2009-03-18
    Sponsor Name:UCB Pharma S.A.
    Full Title: A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotr...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003169-42 Sponsor Protocol Number: 1249.1 Start Date*: 2007-11-30
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001918-42 Sponsor Protocol Number: 2009-107(Canadian) Start Date*: 2014-01-17
    Sponsor Name:Ottawa Hospital Research Institute
    Full Title: Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT) A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4...
    Medical condition: pre-eclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002865-37 Sponsor Protocol Number: DMV02-SIT-026 Start Date*: 2020-11-13
    Sponsor Name:Inmunotek, S.L.
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis With or Without...
    Medical condition: Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and cupressaceae pollen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10036019 Pollen allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003164-31 Sponsor Protocol Number: 3111-302-001 Start Date*: 2019-08-15
    Sponsor Name:Allergan Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS AN ADJUNCT TO ANTIDEPRESSANTS IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ANTIDEPRE...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) PL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-002081-13 Sponsor Protocol Number: GS-2001 Start Date*: 2020-09-08
    Sponsor Name:Gesynta Pharma AB
    Full Title: A Phase II, randomised, multi-centre placebo-controlled, double-blind study to investigate the safety of GS-248, and efficacy on Raynaud’s phenomenon (RP) and peripheral vascular blood flow in pati...
    Medical condition: Raynaud's phenomenon (RP) in patients with Systemic sclerosis (SSc)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037917 Raynauds LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001181-15 Sponsor Protocol Number: FIS-002-2019 Start Date*: 2019-09-17
    Sponsor Name:Fulcrum Therapeutics, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)
    Medical condition: Facioscapulohumeral Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023167-17 Sponsor Protocol Number: 1248.5 Start Date*: 2011-10-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG,
    Full Title: A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 22.7, 45.5, and 90.9 µg...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Completed) FR (Ongoing) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001625-79 Sponsor Protocol Number: AK002-018 Start Date*: 2022-11-21
    Sponsor Name:Allakos Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequatel...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005496-39 Sponsor Protocol Number: APHP211042 Start Date*: 2021-12-20
    Sponsor Name:
    Full Title: Prospective, randomized, double-blind, placebo controlled, multicenter study assessing the efficacy of intracavernosal Clostridium Botulinum neurotoxin type A (Xeomin®) 100U as add-on therapy to si...
    Medical condition: Erectile dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020381 Hormonal imbalance LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001824-13 Sponsor Protocol Number: OXIS Start Date*: 2022-09-12
    Sponsor Name:Leiden University Medical Center
    Full Title: Influence of oxycodone on individuals taking an SSRI
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038678 Respiratory depression PT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2023-000170-97 Sponsor Protocol Number: 2023-01-1200-01 Start Date*: 2023-06-30
    Sponsor Name:LMU Universitätsklinikum München
    Full Title: A single dose of apixaban for the prevention of thrombotic events in the context of long-distance flights
    Medical condition: Symptomatic leg vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002896-32 Sponsor Protocol Number: D5136C00001 Start Date*: 2013-01-16
    Sponsor Name:AstraZeneca AB
    Full Title: A multicenter, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic, safety and tolerability study in patients aged 12 to <18 years of age with a central venous catheter to support pr...
    Medical condition: Thrombosis, thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10050661 Platelet aggregation inhibition PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002713-19 Sponsor Protocol Number: VIB4920.P2.S2 Start Date*: 2020-01-15
    Sponsor Name:Viela Bio, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjögren’s Syndrome (SS)
    Medical condition: Sjögren's syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10059142 Sjoegren's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000007-17 Sponsor Protocol Number: TAK-875_309 Start Date*: 2013-06-05
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride ...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 283  284  285  286  287  288  289  290  291  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 08:28:53 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA